Sign In
Buy CYRX
$16.50
+0.760 (+4.83%)
At Close: Jun 03, 2026
CryoPort, Inc. (CYRX) Reports Q2 Loss, Tops Revenue Estimates
07:35pm, Tuesday, 05'th Aug 2025
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.2. This compares to a loss of $0.33 per share a year ago.
Cryoport Reports Second Quarter 2025 Financial Results
04:19pm, Tuesday, 05'th Aug 2025
Second quarter revenue increased 14% year-over-year to $45.5 million Commercial Cell & Gene Therapy revenue increased 33% year-over-year to $8.7 million Life Sciences Services revenue rose 21% year-ov
CryoPort, Inc. (CYRX) Expected to Beat Earnings Estimates: Should You Buy?
11:01am, Tuesday, 29'th Jul 2025
CryoPort (CYRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CryoPort, Inc. (CYRX) Just Flashed Golden Cross Signal: Do You Buy?
10:56am, Friday, 25'th Jul 2025
CryoPort, Inc. (CYRX) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, CYRX's 50-day simple moving average broke out above its 200-da
Cryoport to Report Second Quarter 2025 Financial Results on August 5, 2025
08:00am, Tuesday, 22'nd Jul 2025
NASHVILLE, Tenn. , July 22, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a global leader in temperature-controlled supply chain solutions for the life sciences, to
Cryoport's MVE Biological Solutions Introduces Next Generation Vapor Shippers
08:00am, Tuesday, 08'th Jul 2025
New SC vapor shipper series improves reliability through extended hold times and patented impact-absorbing and Vapor Shield Technology NASHVILLE, Tenn. , July 8, 2025 /PRNewswire/ -- Cryoport, Inc. (N
What Makes CryoPort, Inc. (CYRX) a Strong Momentum Stock: Buy Now?
01:06pm, Friday, 04'th Jul 2025
Does CryoPort, Inc. (CYRX) have what it takes to be a top stock pick for momentum investors? Let's find out.
CEO Jerrell Shelton Sells Some Shares of Cryoport (CYRX)
11:10am, Monday, 30'th Jun 2025
According to the SEC Form 4 filing on June 26, 2025, Jerrell Shelton, President and CEO, exercised $5 per share options on 16,344 shares of Cryoport (CYRX 4.18%) and proceeded to sell them at $7.0586
CryoPort (CYRX) Upgraded to Buy: Here's What You Should Know
01:01pm, Friday, 27'th Jun 2025
CryoPort (CYRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cryoport Completes CRYOPDP Divestiture and Commences Strategic Partnership with DHL Group
08:00am, Thursday, 12'th Jun 2025
NASHVILLE, Tenn. , June 12, 2025 /PRNewswire/ -- Cryoport, Inc. (Nasdaq: CYRX) ("Cryoport" or the "Company"), a leader in temperature-controlled supply chain solutions for the Life Sciences, with a fo
Wall Street Analysts Believe CryoPort (CYRX) Could Rally 81.43%: Here's is How to Trade
10:56am, Wednesday, 28'th May 2025
The average of price targets set by Wall Street analysts indicates a potential upside of 81.4% in CryoPort (CYRX). While the effectiveness of this highly sought-after metric is questionable, the posit
Does CryoPort (CYRX) Have the Potential to Rally 54.74% as Wall Street Analysts Expect?
11:00am, Monday, 12'th May 2025
The mean of analysts' price targets for CryoPort (CYRX) points to a 54.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Cryoport, Inc. (CYRX) Q1 2025 Earnings Call Transcript
07:15pm, Wednesday, 07'th May 2025
Cryoport, Inc. (NASDAQ:CYRX ) Q1 2025 Results Conference Call May 7, 2025 5:00 PM ET Company Participants Jerrell Shelton - CEO Robert Stefanovich - CFO Mark Sawicki - Chief Scientific Officer Thomas
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
06:21pm, Wednesday, 07'th May 2025
CryoPort, Inc. (CYRX) came out with a quarterly loss of $0.22 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to loss of $0.43 per share a year ago.
Cryoport Reports First Quarter 2025 Financial Results
04:05pm, Wednesday, 07'th May 2025
Commercial Cell & Gene therapy revenue of $7.2 million, up 33% year over year Q1 2025 revenue from continuing operations of $41.0 million, up 10% year over year Supporting 711 global clinical trials a
